We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




HER2 Gene Status Accurately Assessed in Breast Cancer Tissue

By LabMedica International staff writers
Posted on 18 Apr 2011
A fully automated system easily and accurately assesses HER2 gene status in breast cancer tissue.

The system uses an optimized ready-to-use HER2 fluorescence in situ hybridization (FISH) reagent kit with a BOND protocol to produce consistent, high quality stained slides. More...
The system enhances the laboratory workflow, increasing efficiency, and enabling the laboratory to provide a responsive service to their clinicians and clients.

Designed by Leica Microsystems (Buffalo Grove, IL, USA) the HER FISH system detects amplification of the HER2/neu gene via FISH in formalin-fixed, paraffin-embedded (FFPE) human breast cancer-tissue specimens. The Leica HER2 FISH System is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered.

Designed for easy and accurate assessment of HER2 gene status in breast cancer tissue, the Leica HER2 FISH System combines the use of the gold standard PathVysion HER2 FISH probes, supplied by Abbott Molecular Inc. (Des Plaines, IL, USA) with Leica's industry-leading BOND automated platform, delivering accurate results for diagnostic confidence.

The Leica HER2 FISH System was compared to the Abbott Molecular PathVysion HER2 DNA probe kit assay on an independent set of samples and found to provide acceptably concordant results. The actual correlation of the results of the Leica HER2 FISH System to clinical outcome has not been established.

Related Links:
Leica Microsystems
Abbott Molecular Inc.




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.